Structural Mechanisms in the Abolishment of VEGF-induced Microvascular Hyperpermeability by cAMP
Introduction
Microvascular hyperpermeability is the critical step for the abnormal transport of molecules and cells across the blood vessel wall and thus the crucial step in many pathological processes including tumor growth and metastasis ͓1͔. Vascular endothelial growth factor ͑VEGF͒, a family of tumor angiogenic factors, has long been recognized as a permeability-enhancing agent both in vivo and in vitro ͓2-10͔. Recent advances in the understanding of the molecular mechanisms of VEGF action have led to many models for intervention in VEGF-mediated pathways in therapy for solid tumor. These include antibodies to block the binding of VEGF to its cellular receptors, chemical inhibitors of the tyrosine kinase functions of the VEGF receptors, and antisense nucleic acids to interfere with VEGF production ͓11-16͔. However, strategies targeting VEGF-mediated microvessel hyperpermeability by enhancing the barrier function of the microvessel wall have not been well developed ͓14,15͔.
Previous studies have found that increased intracellular levels of adenosine 3Ј ,5Ј-cyclic monophosphate ͑cAMP͒ can block the inflammatory response in many experimental models. Simultaneous stimulation of adenylate cyclase ͑either by activating prostaglandin receptors or by stimulating adenylate cyclase directly with forskolin͒ and phosphodiesterase ͑PDE͒ inhibition with zardaverine ͑a strong inhibitor of PDE type III and type IV͒ was highly effective in inhibiting permeability increases induced by H 2 O 2 in isolated rabbit lung ͓17͔. Elevation of cAMP also blocks monolayer permeability stimulated by histamine ͓18͔, phorbol myristate acetate ͓19͔, thrombin, and hemolysin ͓20͔. A previous study on intact microvessels also confirms the blocking effect of a cAMP analog on inflammatory stimulation ͓21͔. Solutions containing adenosine triphosphate ͑ATP͒ ͑10 m͒ stimulate a five-to ten-fold increase in microvessel hydraulic conductivity ͑L p ͒ in both capillaries and postcapillary venules of frog and hamster mesentery. This characteristic transient inflammatory response was nearly abolished by 15 min pretreatment with 8-bromo-adenosine 3Ј ,5Ј-cyclic monophosphate ͑2 mM͒. The first aim of this study is to test the hypothesis that elevation of the intraendothelial cAMP levels also abolishes or attenuates the transient increase in microvascular permeability by VEGF in intact microvessels in vivo.
The cleft between adjacent endothelial cells is widely believed to be the principal pathway for water and hydrophilic solute transport through the microvessel wall under normal conditions and it is also suggested to be the pathway for the transport of high molecular weight plasma proteins, leukocytes and tumor cells across microvessel walls in disease. Inside the interendothelial cleft, tight junctions appear as discrete sites of fusion between the outer plasma membrane of adjacent cells when visualized in ultrathin section electron microscopy ͓22͔. They create an intercellular barrier for material transport across the microvessel wall and can be regulated by response to physiological and tissue-specific requirements ͓23,24͔. In response to stimuli, tight junctions are able to rapidly change their functional properties, which permit dynamic fluxes of fluids and solutes in addition to the passage of whole cells ͓25͔. Using cell monolayer, many in vitro studies have showed that 3Ј ,5Ј-cyclic monophosphate ͑cAMP͒ induces decreased paracellular permeability by a mechanism correlated to an increase in tight junction number or complexity ͓26-30,20͔.
To understand the underlying mechanism of the regulation of microvessel permeability by elevated intracellular cAMP levels in vivo, Adamson et al. ͓26͔ tested the cAMP effect on microvessel hydraulic conductivity L p from the control state in intact frog mesenteric microvessels. They found that increased cAMP levels by simultaneous adenylate cyclase activation ͑by forskolin, 5 M͒ and phosphodiesterase inhibition ͑by rolipram, 10 M͒ had reduced L p to 37% of its baseline value in ϳ20 min. In another study using quantitative fluorescence microscope photometry, Fu et al. ͓31͔ performed the study of cAMP effect on microvessel solute permeability ͑P͒ to different sized solutes. They found that the permeability to sodium fluorescein ͑0.45 nm radius͒ P sodium fluorescein and to ␣-lactalbumin ͑2.01 nm radius͒ P ␣-lactalbumin decreased gradually with time after introducing forskolin ͑5 M͒ and rolipram ͑5 M͒. In ϳ20 min, P sodium fluorescein and P ␣-lactalbumin were reduced to 67% and 64% of their baseline values, respectively. Furthermore, Adamson et al. ͓26͔ found in their electron microscopy study that cAMP effect would induce an increase in the number of tight junction strands from a mean value of 1.7 to a mean value of 2.2 per cleft after 20 min treatment of forskolin ͑5 M͒ and rolipram ͑10 M͒. A mathematical model developed by Fu and Chen ͓32͔ for the modulation of microvessel permeability by junction strands reconciled the measured data for microvessel permeability to water and solutes and the structural changes observed by electron microscopy, and further confirmed that cAMP induced decrease in microvessel permeability from control is correlated to the increased number of the junction strands in the interendothelial cleft. More junction strands may induce more tortuosity in the interendothelial cleft, thus will decrease the microvessel permeability to water and solutes.
The structural mechanisms which have been studied to increase microvessel permeability by VEGF, inflammatory mediators and physical stimuli involve the formation of gaps between adjacent endothelial cells in venular microvessels ͓33͔, vesiculo-vacuolar organelles ͑VVOs͒ pathways ͓34,35͔, transcellular pores ͓34,36͔, and fenestra ͓34,37͔. These structural changes were observed from a sample at least 10 min later after VEGF treatment. For acute increase ͑less than 1 min͒ in microvessel permeability induced by VEGF, Fu and Shen ͓7͔ suggested that the most likely structural changes would be a ϳ2.5-fold increase in the width of the cleft between endothelial cells forming the microvessel wall and partial degradation of endothelial surface glycocalyx. The second aim of this study is to investigate the corresponding changes in the barrier function of microvessel walls in the abolishment of the VEGF-induced hyperpermeability by elevation of intracellular cAMP levels. We shall address this issue by in vivo permeability measurements to different sized solutes under various permeability conditions and by fitting the permeability-molecular size profiles obtained in the experiments with the prediction of the mathematical model from Fu et al. ͓7, 38͔ and Fu and Chen ͓32͔. The solute permeability ͑P͒ was measured by using quantitative fluorescence microscope photometry ͓39,31͔. All experiments have been performed on individually perfused venular microvessels in frog mesentery. Each microvessel was perfused via two sides of a pipette with two lumens to enable the perfusate to be switched rapidly from a clear ͑washout͒ perfusate to one containing the fluorescently labeled test solute. This method enabled us to repeat measurements of the solute permeability under more than one chemical treatment on each microvessel. In addition, the permeability was measured by perfusing segments of the microvessel with fluorescently labeled solutes under conditions in which the transmural differences of solute concentration and hydrostatic pressure were known.
Methods

Solutions
Ringer Solutions and Albumin-Ringer Perfusates. Frog Ringer solution was used for all dissections, perfusates, and superfusates. The composition of frog Ringer solution was ͑in mM͒: 111 NaCl, 2.4 KCl, 1.0 MgSO 4 , 1.1 CaCl 2 , 0.195 NaHCO 3 , 5.5 glucose, and 5.0 HEPES. The pH was balanced to 7.4-7.45 by adjusting the ratio of HEPES acid to base. In addition, both the clear solution and the fluorescent dye solution contained BSA ͑A4378, Sigma͒ at 10 mg/ ml.
Fluorescent Test Solute Preparation
Sodium fluorescein. Sodium fluorescein ͑F6377, Sigma; mol wt 376, Stokes-Einstein radius ϳ0.45 nm͒ was dissolved at 0.1 mg/ ml in frog Ringer solution containing 10 mg/ ml BSA. The solution was made fresh on the day of use to avoid binding to the serum albumin ͓31͔.
FITC-labeled ␣-lactalbumin and BSA. ␣-lactalbumin ͑L6010, Sigma; mol wt 14,176, Stokes-Einstein radius ϳ2 nm͒ and BSA ͑A4378, Sigma; mol wt approx. 67,000, Stokes-Einstein radius ϳ3.5 nm͒ were labeled with fluorescein isothiocyanate ͑FITC͒ ͑F7250, Sigma, mol wt 389.4͒ as follows ͓31,7͔. Protein ͑90 mg͒ was dissolved in 15 ml of borate buffer ͑0.05 M, pH ϳ 9.3, 20°C͒ containing 0.4 M NaCl. The solution was placed in 18-mm-diameter dialysis tubing with a 3500-mol wt cutoff ͑Spec-trum Medical Industries͒ and was dialyzed for 12 h with constant stirring at 15°C against 50 ml of the borate buffer containing FITC ͑0.5 mM͒. The labeled protein then was dialyzed against 2 l of glucose-free frog Ringer solution twice, each time for 12 h. The dialysis procedure was repeated twice further with 2 l of normal Ringer solution until there was no free dye. The influence of free dye on measured permeability to a labeled protein was discussed in Refs. ͓31,7͔. The FITC-labeled ␣-lactalbumin and BSA were stored frozen and used within 2 weeks of preparation. On the day of use, unlabeled BSA was added to aliquots of the labeled protein. The final FITC-␣-lactalbumin and FITC-BSA dye concentration used in the experiment were 2 mg/ ml in albuminRinger solution. For this preparation, the fluorescence intensity from the free FITC dye was less than 1% of the solution with labeled proteins, which was checked using the photometer at the same instrument settings used in our experiments.
All dye solutions described above were kept chilled until just before use and were discarded at the end of the day.
Quantitative Fluorescence Microscope Photometry for P Measurement. Instead of using two pipettes cannulating the two arms at a Y-branched microvessel in permeability measurement ͓39,31͔, we cannulated the microvessel with a double-barreled pipette. The design of pipette and its holder was modified from Davis and Gore ͓40͔ and McKay and Huxley ͓41͔. Briefly, a small hole was first ground in one side of a thin-walled glass pipette ͑1.5 mm OD, 102 mm length, Sutter Instrument, Novato, CA͒, ϳ1.5 cm from one end, using a diamond disk ͑Rx Honing Machine, Mishawaka, IN͒. After being cleaned and dried in the same way as for general single-barreled pipettes ͓39,31͔, the pipette was drawn using a Flaming/Brown micropipette puller ͑Model P-87, Sutter Instrument, Novato, CA͒. The tip, which is ϳ8 cm from the other end of the pipette, was beveled similarly to a single-barreled pipette ͓39͔. The final tip length is from 20 to 40 m with a width 10-15 m. The channel with the small ground hole on side ͑dye side͒ was backfilled with optical cement ͑Norland Optical Adhesive 63, New Brunswick, NJ͒ and cured under ultraviolet light ͑UVP, San Gabriel, CA͒ for 10-15 min.
Before inserting the pipette into the holder, both pipette channels were filled with perfusate solutions using 3.5-in., 30-gauge hypodermic needles ͑Hamilton, Reno, NV͒. The pipette was then inserted into the holder so that the small hole on the dye side channel was aligned within the chamber between two O-rings in the holder. This arrangement allowed alternate perfusion of the cannulated vessel with a washout solution containing no fluorescent solute or the solution containing the fluorescent solute ͑dye͒. Each channel of the pipette was connected to a water manometer, which enabled perfusion at known pressures. In our experiments the pressure in the microvessel was estimated to be
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Transactions of the ASME 5-10 cm H 2 O, as determined by balancing the interface between fluorescent and nonfluorescent solutions within the nonflowing channel of the pipette. A detailed description of the method used to measure P of fluorescently labeled solutes has been published ͓39,31,7͔. In the current experiment we used a different but similar experimental setup. A Nikon Eclipse TE-300 inverted fluorescence microscope was used to observe the mesentery. A ϫ 10 lens ͑NA 0.3, Nikon͒ gave a field of view of ϳ2 mm in diameter. The tissue was observed with either transmitted white light from a light pipe held suspended above the preparation or with fluorescent light from a xenon lamp ͑300 W, Intracellular Imaging Inc.͒ with appropriate filter sets for fluorescein. The filter set, Omega XF23, which was used for sodium fluorescein, FITC-BSA and FITC-␣-lactalbumin, consisted of an excitation filter ͑485DF22͒, a dichroic mirror ͑505DRLP͒, and an emission filter ͑535DF35͒. The intensity of the Xenon light source is controlled by an attenuator knob on the front panel of the lamp house. The intensity of the light output can be adjusted from 0 to 100%. To reduce the tissue damage due to the exposure to fluorescence light, the light intensity was kept as low as possible. Further protection was provided by using an experimental protocol in which the time of tissue exposure to the excitation light was kept as short as possible for the permeability measurement. Generally, the exposure time for an individual measurement was 5 -20 s. The larger the molecule was, the longer the exposure time would be. The fluorescence intensity ͑I f ͒ in the capillary lumen and surrounding tissue was measured by aligning the vessel segment within an adjustable measuring window consisting of a rectangular diaphragm in the light path. The maximum size of the window is 250 m wide and 650 m long. In our experiment, the dimensions of the measuring window were generally 100-200 m wide ͑roughly five times the microvessel diameter͒ and 300-400 m long. The measuring window was set at least 100 m from the base of the vessel to avoid solute contamination from the side arm. I f measured by a photometer ͑HC135-11, Hamamatsu͒, was recorded into a computer through an A/D board by using InCyt Pm1™ Photometry software ͑Intracellular Imaging Inc.͒. Compared to previous strip chart recorder, this type of recording greatly improves the spatial and temporal resolution of the intensity versus time curve, which is used to calculate solute permeability P. P = ͑1/⌬I f0 ͒͑dI f / dt͒ 0 ͑r /2͒, where ⌬I f0 is the step increase in fluorescent light intensity as the test solute fills the microvessel lumen, ͑dI f / dt͒ 0 is the initial rate of increase in fluorescence light intensity after solute fills the lumen and begins to accumulate in the tissue, and r is the microvessel radius ͓39,31͔. Calibration Experiments. We used both in vitro and in vivo calibration experiments to test the assumption in the calculation of P, that the fluorescent intensity I f is a linear function of the number of solute molecules in the measuring field. We used the same instrument settings in the calibration experiments as those in permeability measurements. For different sized test solutes, we use different instrument settings by adjusting the intensity attenuator knob in the lamp house to get enough fluorescent intensity for the measurement, but to avoid tissue damage due to the exposure to the fluorescent light. The detailed calibration procedures were given previously ͓31,7͔. Both in vitro and in vivo calibrations showed that the relationship between the concentration and the fluorescence intensity was linear from 0.05 to 0.2 mg/ ml for sodium fluorescein, from 0.3 to 6 mg/ ml for FITC-␣-lactalbumin and BSA. The concentrations used in our experiments were: 0.1 mg/ ml for sodium fluorescein, 2 mg/ ml for both FITC-␣-lactalbumin and FITC-BSA.
In addition, we found in the in vitro photobleaching experiment that sodium fluorescein ͑0.1 mg/ ml͒, FITC-␣-lactalbumin and FITC-BSA ͑2 mg/ml͒, I f values fell about 0.4%, 0.3%, and 0.7% of their original values in 1 min, correspondingly. The 1 min was typically two to four times as long as the exposure time required for an individual solute permeability measurement. The much lower degree of photobleaching than previous settings ͓39,31͔ was due to the reduced excitation light intensity by adjusting the attenuator knob of the light source. In addition, the shorter exposure time for larger solute ͑BSA͒ in an individual permeability measurement was due to much higher sensitivity of the current computer recording system ͑dI / I f0 ϳ 1 / 10,000͒ than that previously used strip chart recorder ͑ϳ1͒. In general, the current system is 100 times as sensitive as the chart recorder ͓7͔.
Experimental Protocol. To test the role of cAMP on VEGFinduced microvessel hyperpermeability, for each test solute, after making several control measurements when the washout side was filled with Ringer perfusate containing BSA ͑10 mg/ ml, 1% BSA͒ and the dye side was filled with the same perfusate to which the test solute was added, we replaced the pipette by a new pipette with both washout and test sides containing 8-bromo-cAMP ͑Sigma, 2 mM͒. The concentration of 8-bromo-cAMP was chosen to be consistent with that used in Ref. ͓21͔ . During the replacement of the new pipette, the pressures for both washout and dye sides of the pipette were dropped to Ͻ1 cm H 2 O, so there was negligible flow at the tip during recannulation. Then, the pressure at washout side was increased to 20-30 cm H 2 O, while the pressure at the dye side was to 5 -10 cm H 2 O to balance the pressure at washout side. These pressure settings were for the perfusion of washout solution. For dye perfusion, after 10-15 s perfusion with washout containing 8-bromo-cAMP, the pressure at dye side was switched to 20-30 cm H 2 O, while pressure at washout side switched to 5 -10 cm H 2 O. The perfusion of dye solution containing 2 mM 8-bromo-cAMP lasted 5 -15 s, depending on the solute size. From the initial step increase in fluorescence intensity of the test dye solution and its accumulation in the measuring window ͑please see previous section͒, we can calculate the solute permeability P. During the washout perfusion, the test solute was washed out of the measuring window through the vessel and enabled repeated permeability measurements of the same test solute at different times. In this way, P was measured every 5 ͑±2͒ min during cAMP treatment. After ϳ20 min pretreatment of 2 mM 8-bromo-cAMP, we finally replaced the pipette by another new pipette with both washout and test sides that contained 8-bromocAMP ͑2 mM͒ and 1 nM VEGF ͑human recombinant VEGF 165 , Peprotech, Rocky Hill, NJ͒. The concentration of VEGF was chosen to be consistent with that used in Refs. ͓3,7͔. P was measured every 15-30 s including both dye ͑5-15 s͒ and washout perfusion ͑10-15 s͒. The alternating perfusion of dye and washout solutions lasted ϳ5 min.
The protocol for the matched control groups was the same as for the test groups except using 1% BSA Ringer perfusates without 8-bromo-cAMP.
Analysis and Statistics. P measurements during the control period in a vessel were averaged to establish a single value for control P. This value was then used as a reference for all subsequent measurements on that vessel. To present data at a specific time for acute effect, individual measurements were grouped within 15-30 s intervals. For example, for P at 15 s, individual measurements starting before and at 15 s of washout perfusion were averaged. For VEGF or cAMP/VEGF treatment, grouping was at 15 s ͑0-15 s͒, 30 s ͑16-30 s͒, 45 s ͑31-45 s͒, 60 s ͑46-60 s͒, 90 s ͑61-90 s͒, etc. For cAMP treatment, grouping was at 5 min ͑3-7 min͒, 10 min ͑8-12 min͒, 15 min ͑13-17 min͒, 20 min ͑18-23 min͒. The nonparametric Wilcoxon signed-rank test was applied to the averaged P data to test statistical significance of the treatment over time. Mann-Whitney's U test was applied to between-group data to test for P differences at specific times. Significance was assumed for probability levels p Ͻ 5%.
Results
Perfusion with solutions containing 2 mM 8-bromo-cAMP elicited a consistent decrease in apparent permeability P for all three molecules, and abolished the transient increase induced by 1 nM VEGF. The paired measurements of P in individual frog mesenteric microvessels are shown in Fig. 1 . In the matched control group, shown in ᭺, baseline P was first measured with frog Ringer solution containing 1% BSA, then P was measured in a sham experiment of reperfusion with the control solution for about 20 min, and finally the P was measured with perfusion of 1% BSA containing 1 nM VEGF. In Fig. 1͑a͒ , ᭺ shows the control measurement in one venular capillary for sodium fluorescein. P sodium fluorescein did not fall after 20 min perfusion with the control solution, however, it had a transient increase of 2.5-fold of its baseline value at 26 s after perfusion with 1 nM VEGF and returned to its baseline in ϳ2 min. The matched control measurements for ␣-lactalbumin and BSA are shown by symbol ᭺ in Figs. 1͑b͒ and 1͑c͒ . There were no falls in P ␣-lactalbumin and P BSA after 20 min perfusion with the control solution but a 3.2-fold and a 5.4-fold transient increases at 28 and 30 s, respectively, after the treatment of 1 nM VEGF. The increased permeability returned to control in ϳ2 min. These behaviors are the same as those reported in Fu and Shen ͓7͔. The test results are shown in b. For each test solute, after making several measurements by perfusing the control solution ͑1% BSA frog Ringer͒ to establish a baseline P control , we recannulated the same microvessl with perfusate containing 2 mM 8-bromo-cAMP to increase the cAMP levels and made measurements once for every 5 ͑±2͒ min interval up to 20 min, and finally, we replaced the pipette and measured P with perfusate containing 2 mM 8-brocmo-cAMP and 1 nM VEGF. In Fig. 1͑a͒ , b shows that in one typical venular capillary, P sodium fluorescein started to fall within 5 min and fell further with time. P sodium fluorescein fell to 59% of its baseline value at ϳ20 min in this microvessel. After 20 min pretreatment of 2 mM 8-brocmocAMP, there was no transient increase in P sodium fluorescein with perfusion of 1 nM VEGF and 2 mM 8-brocmo-cAMP. At 28 s after the treatment of 1 nM VEGF/ 2 mM 8-brocmo-cAMP, the P sodium fluorescein was 99% of its baseline value. Symbols b in Figs. 1͑b͒ and 1͑c͒ show the effects of cAMP on P ␣-lactalbumin and P
BSA
. Similarly, P ␣-lactalbumin and P BSA fell to 30% and 25% of their baseline values at 20 min after perfusion with 2 mM 8-brocmo-cAMP. The transient increase due to 1 nM VEGF was abolished in both P ␣-lactalbumin and P BSA with the 20-min pretreatment of 2 mM 8-brocmo-cAMP. At 29 and 22 s after perfusion with 1 nM VEGF/ 2 mM 8-brocmo-cAMP, P ␣-lactalbumin and P BSA were 71% and 51% of their baseline values, respectively. Figure 2 summarizes the results from a series of individual measurements shown in Fig. 1 . The permeability values at specific time moments are presented in Table 1 . Figure 2͑a͒ shows the results for P sodium fluorescein . In the matched control group, after control and 20 min sham experiments, P sodium fluorescein ͑Mean± SE͒ in five vessels, measured at the peak of the response ͑25± 5 s͒ to 1 nM VEGF, was 6.6± 1.2ϫ 10 −5 cm/ s, compared with a baseline P of 2.4± 0.26ϫ 10 −5 cm/ s. This represents a mean peak increase in P sodium fluorescein of 2.6± 0.4-fold compared with the baseline in the same vessel ͑p Ͻ 0.01͒. In the test group, after 20 min treatment of 2 mM 8-brocmo-cAMP, P sodium fluorescein ͑Mean± SE͒ in nine vessels decreased from 2.3± 0.10 ϫ 10 −5 cm/ s ͑range 1.8-2.8ϫ 10 −5 cm/ s͒ to 1.4± 0.08 ϫ 10 −5 cm/ s ͑range 1.0-1.7ϫ 10 −5 cm/ s, p Ͻ 0.01͒, representing a mean ratio of 0.55± 0.045 ͑range 0.34-0.8͒. The pretreatment of 2 mM 8-brocmo-cAMP abolished the VEGF-induced transient increase. At ϳ30 s after perfusion with 1 nM VEGF/ 2 mM 8-brocmo-cAMP, P sodium fluorescein in nine vessels was 2.1± 0.17 ϫ 10 −5 cm/ s ͑range 1.3-2.8ϫ 10 −5 cm/ s͒, which had no significant difference from the baseline values ͑p Ͼ 0.15͒. The mean ratio to baseline was 0.96± 0.066 ͑range 0.71-1.27͒. Figure 2͑b͒ shows the results for P ␣-lactalbumin . In the matched control group, after control and 20 min sham experiments, P ␣-lactalbumin ͑Mean± SE͒ in four vessels, measured at the peak of the response ͑26± 2 s͒ to 1 nM VEGF, was 1.6± 0.22 ϫ 10 −5 cm/ s, compared with a baseline P of 0.61± 0.022 ϫ 10 −5 cm/ s. This represents a mean peak increase in P ␣-lactalbumin of 2.7± 0.3-fold compared with the baseline in the same vessel ͑p Ͻ 0.01͒. In the test group, after 20 min treatment of 2 mM 8-brocmo-cAMP, P ␣-lactalbumin ͑Mean± SE͒ in ten vessels decreased from 0.65± 0.019ϫ 10 −5 cm/ s ͑range 0.55-0.72 ϫ 10 −5 cm/ s͒ to 0.25± 0.036ϫ 10 −5 cm/ s ͑range 0.15-0.47 ϫ 10 −5 cm/ s, p Ͻ 0.01͒, representing a mean ratio of 0.37± 0.051 ͑range 0.21-0.65͒. The pretreatment of 2 mM 8-brocmo-cAMP abolished the VEGF-induced transient increase. At ϳ30 s after perfusion with 1 nM VEGF/ 2 mM 8-brocmo-cAMP, P ␣-lactalbumin in ten vessels was 0.48± 0.035ϫ 10 −5 cm/ s ͑range 0.23ϫ 0.62 ϫ 10 −5 cm/ s͒, which was smaller than the baseline values ͑p Ͻ 0.01͒. The mean ratio to baseline was 0.76± 0.07 ͑range 0.35-1.12͒. Figure 2͑c͒ shows the results for P BSA . In the matched control group, after control and 20-min sham experiments, P BSA ͑Mean± SE͒ in four vessels, measured at the peak of the response ͑27± 2 s͒ to 1 nM VEGF, was 0.46± 0.091ϫ 10 −5 cm/ s, compared with a baseline P of 0.069± 0.0081ϫ 10 −5 cm/ s. This represents a mean peak increase in P BSA of 6.5± 1.0-fold compared with the baseline in the same vessel ͑p Ͻ 0.01͒. In the test group, after 20 min treatment of 2 mM 8-brocmo-cAMP, P 
Discussion cAMP
Effect on VEGF-Induced Microvessel Hyperpermeability. Many agents are known to increase microvessel permeability, but a few are known to decrease permeability. Progress has been made in the identification of barrier enhancing agents ͓15͔ that can decrease the vessel permeability. cAMP is one of the few substances that improve endothelial barrier function. Elevation of endothelial cAMP effectively reduced the permeability of endothelial cells both in vitro and in vivo ͓42, 26,27,21,29,17,20,15͔ , and under both basal conditions and stimulated states such as in ischemia-reperfusion injury ͓42͔, and after exposure to inflammatory agents, e.g., histamine, thrombin, ATP, H 2 O 2 , etc. ͓21,19,28,17,18,20͔ . In addition, the effect does not depend on whether cAMP is elevated by activation of adenylate cyclase or by the inhibition of cAMP-degrading phospodiesterases ͓28,30,20͔, which broadens possible therapeutic approaches ͓15͔. To search for the barrier-improving agents that can protest against microvascular hyperpermeability during tumor growth and metastasis, the first aim of our study is to test the hypothesis that elevation of the intraendothelial cAMP levels also abolishes/attenuates the transient increase in microvascular permeability by a tumor angiogenic factor, vascular endothelial growth factor ͑VEGF͒, in intact microvessels. The experimental results for the permeability to small, intermediate and large sized solutes in frog mesenteric microvessels have confirmed our hypothesis. In addition, Figs. 2͑a͒-2͑c͒ show that the lines for P under cAMP/VEGF treatment are slightly lower than those under In the matched control group, baseline P was first measured with Ringer perfusate containing 1% BSA "bovine serum albumin, 10 mg/ ml…, then P was measured in a sham experiment of reperfusion with control solution for È20 min, and finally the P was measured under the treatment of 1 nM VEGF for È5 min. In the test group, baseline P was first measured with perfusate containing 1% BSA, then P was measured in the test experiment of reperfusion with the same solution also containing 2 mM 8-bromo-cAMP for È20 min, and finally the P was measured under the treatment of 1 nM VEGF and 2 mM 8-bromo-cAMP for È5 min. "a… measurement for P sodium fluorescein ; "b… measurement for P ␣-lactalbumin ; "c… measurement for P BSA .
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JUNE 2006, Vol. 128 / 321 Fig. 2 Effect of cAMP on VEGF-induced hyperpermeability in frog mesenteric microvessels for "a… sodium fluorescein, "b… ␣-lactalbumin, and "c… BSA "bovine serum albumin…. Mean± SE P relative to baseline plotted as a function of time. In the matched control group "᭺, BSA-BSA-VEGF…, baseline P was first measured with Ringer perfusate containing 1% BSA "bovine serum albumin, 10 mg/ ml…, then P was measured in a sham experiment of reperfusion with control solution for È20 min, and finally the P was measured under the treatment of 1 nM VEGF for È5 min. In the test group "b, BSA-cAMP-VEGF…, baseline P was first measured with perfusate containing 1% BSA, then P was measured in the test experiment of reperfusion with the same solution also containing 2 mM 8-bromo-cAMP for È20 min, and finally the P was measured under the treatment of 1 nM VEGF and 2 mM 8-bromo-cAMP for È5 min. ‫ء‬ p < 0.05 compared with the baseline. Table 1 Control and test values of apparent solute permeability induced by 2 mM 8-bromocAMP "after È20 min treatment… and 2 mM 8-bromo-cAMP/1nMVEGF "after È30 s treatment… in same vessels of frog mesentery. Values are means± SE; n, number of vessels. VEGF, vascular endothelial growth factor. L is the total depth of the cleft "È400 nm…, L jun is the thickness of the junction strand "È10 nm…, and L 1 and L 3 are depths between the junction strand and luminal and abluminal fronts, respectively. L f "È100 nm… is the thickness of fiber matrix at cleft entrance. Distance between two adjacent breaks in junction strand is 2D "È2500 nm…, and 2d "È150 nm… is the width of large junction breaks. At the entrance of the cleft on the luminal side, surface glycocalyx structures are represented by a periodic square array of cylindrical fibers. Radius of these fibers is a, and gap spacing between fibers is ⌬. "b… Three-dimensional sketch. There are two types of pores in the junction strand. Large breaks: 2d Ã 2B = 150Ã 20 nm; small continuous slit: 2b s É 1.5 nm. Fu and Shen †7 ‡ suggested that 2B is increased to 50 nm, 2.5-fold of 20 nm under normal conditions, when the permeability is transiently "at È30 s… increased by 1 nM VEGF.
VEGF treatment in the later time after the transient increase by VEGF. This implies the stabilizing effect of cAMP on permeability.
Structural Mechanisms of cAMP Effect on VEGF-Induced Microvessel Hyperpermeability. The signaling mechanisms governing VEGF control of microvessel hyperpermeability are fairly known: activation of endothelial receptors, followed by fluxes of calcium ions, nucleotides, phospholipids, and ionic second messengers, leads to cytoskeleton tension and the increase of vessel permeability ͓4,5͔. However, the ultimate sites of regulation in the transendothelial pathway of solute transport are the structural components of the microvessel wall, and traditional cell signaling studies have not extended to include this final, and most important, target. Although intercellular, transcellular and other pathways induced by VEGF were observed by electron microscopy ͓5,34,36,35,37͔, they were structural changes after longer time ͑at least 10 min͒ of VEGF perfusion. By combining in vivo permeability measurements to molecular probes with characteristic sizes and the predictions from mathematical modeling, Fu and Shen ͓7͔ suggested the structural changes in the interendothelial cleft that could account for the transient ͑ϳ30 s͒ increase in microvessel permeability by VEGF.
The interendothelial cleft, which is shown in Fig. 3 ͓38͔, is the paracellular pathway for water and solute transport across the microvessel wall ͓8͔. Its structural components, the junction strands with pores, the surface glycocalyx, and the cleft width, form the barriers between the blood and tissue that maintain the normal microvessel permeability to water and solutes. Changes in these structural components induce the changes in microvessel permeability. On the basis of measured permeability data, the model prediction in Ref. ͓7͔ suggested that the transient increase ͑at ϳ30 s͒ in permeability by 1 nM VEGF are due to a ϳ2.5-fold increase in the width of the cleft ͑2B in Fig. 3͑b͒͒ between endothelial cells forming the microvessel wall and partial degradation of the endothelial surface glycocalyx.
Tight junctions ͑junction strands in the cleft͒ create a regulated paracellular barrier to the movement of water, solutes, and cells between endothelial cells ͓23,25,37,44,46-49͔. Many previous studies have found in a variety of experimental models that increased intracellular cAMP can decrease the water and solute permeability by possibly increasing the number of junction strands or complexity in the paracellular cleft ͓26,30,45͔. Adamson et al. ͓26͔ found in their electron microscopy study that cAMP effect would induce an increase in the number of tight junction strands from a mean value of 1.7 to a mean value of 2.2 per cleft after 20 min treatment of forskolin ͑5 M͒ and rolipram ͑10 M͒. Meanwhile, the hydraulic conductivity L p decreased to 37%, the permeability to sodium fluorescein P sodium fluorescein and to ␣-lactalbumin P ␣-lactalbumin decreased to 67% and 64% of their respective baseline values ͓31͔. The mean value of 1.7 junction strands per cleft under normal conditions came from a distribution of the number of junction strands from 0 to 5 with 41% clefts having one strand, ϳ39% having two strands, and ϳ14% having three strands. When increasing the cAMP level, the mean value of 2.2 per cleft was from a distribution of ϳ20% clefts having one strand, ϳ48% having two strands, ϳ20% having three strands, and the rest having zero, four, or five strands. The largest shift was from one to two strands. Based on the above experimental observations, Fu and Chen ͓32͔ proposed a mathematical model for the modulation of microvessel permeability by tight junction strands. They hypothesized that cAMP would on average increase the number of junction strands from 1 to 2 for the aforementioned experiments. Figure 4 shows their model. Under this assumption, they predicted that L p decreased to 37%, P sodium fluorescein to 56%, and P ␣-lactalbumin 47% of their corresponding control values. These data were slightly lower than those measured in the experiments because in the model, the junction strand was increased from 1 to 2 ͑100% increase͒, instead of from 1.7 to 2.2 ͑29% increase͒ observed by the electron microscopy. The model in Ref. ͓32͔ was based on the assumption that there are no other structural changes in the cleft such as the number of the large pores, the large pore size, the width and the length of the cleft, and the thickness and arrangement of the surface glycocalyx. However, this assumption was validated by direct and indirect evidence using electron microscopy and reflection coefficient measurements. After carefully examining and surveying their samples, Adamson et al. ͓26͔ concluded that cAMP did not close preexisting gaps ͑junction pores͒ and did not increase cell to cell overlap or endothelial cell spreading. Although there has been no direct investigation to test the effect of cAMP on the structure of endothelial surface glycocalyx, the reflection coefficient of ␣-lactalbumin appeared not to be affected by cAMP ͓26,31͔.
The signaling mechanisms in the modulation of microvessel permeability by cAMP are summarized in Ref. ͓43͔ . Elevation of cAMP levels activates cAMP-dependent protein kinase, which either increases the tight junction strands of the interendothelial cleft ͓26͔, or phosphorylates myosin light chain kinase to induce myosin relaxation ͓19͔. Both actions decrease the microvessel permeability or prevent the permeability increase by inflammatory agents. The second aim of this study is to test the hypothesis that the abolishment of the VEGF-induced hyperpermeability by cAMP is due to the increase in tight junction strands in the interendothelial cleft by applying the model in Ref. ͓32͔ . More junction strands provide more resistance to water and solute transport ͑see Fig. 4͒ and compensate the effect of increase in the cleft width 2B by VEGF, which was predicted in Ref. ͓7͔ . In addition, more junction strands reinforce barrier function of the cleft and make it harder for VEGF to increase the cleft width. We combined the models from Refs. ͓7,32͔ and hypothesized that the abolishment is due to the increase in the number of junction strands from 1 to 2 ͑in an average sense͒, the reduced increase in the width of the cleft, and the recovery of the surface glycocalyx layer. Figure  5 demonstrates our model predictions. In Fig. 5 , the control values Fig. 6 Comparison of experimental data with the model predictions under various conditions for diffusive permeability P d of frog mesenteric microvessels to "a… sodium fluorescein, "b… ␣-lactalbumin, and "c… BSA "bovine serum albumin…. Under VEGF treatment, the model prediction is based on increasing the width of the interendothelial cleft by 2.5-fold and reducing the thickness of the glycocalyx layer by half †7 ‡; under cAMP treatment, the model prediction is based on increasing the number of junction strands in the cleft †32 ‡; and under cAMP/VEGF treatment, the model prediction is based on increasing the number of the junction strands in the cleft from 1 to 2, reducing the increase in the cleft width from 2.5-to 1.5-fold and restoration of the glycocalyx layer.
are those without any treatment. That is when there is one junction strand in the middle of the cleft, the cleft width 2B =20 nm, the length L = 400 nm, the width of the large junctional pore 2d = 150 nm and the spacing between large pores 2D = 2640 nm, the width of the continuous small slit 2b s = 1.4 nm, and the thickness of the surface glycocalyx L f = 100 nm ͑Fig. 3, Ref. ͓38͔͒. Results shown in Fig. 5͑a͒ indicate that when there are two junction strands in the cleft, the increase in the cleft width will not increase the permeability to the solutes as much as when there is just one junction strand ͑Fig. 7 in Ref. ͓7͔͒. Figure 6 shows the comparison of experimental data with the model predictions under various conditions for diffusive solute permeability ͑P d ͒ of frog mesenteric microvessels to solutes with different sizes. Taking into account the influences from the solvent drag and free dye, the ratio of diffusive permeability ͑P VEGF / P control ͒ d is 91% of the ratio of apparent permeability P VEGF / P control for ␣-lactalbumin and 90% of that for BSA ͓7͔. Whereas, ͑P cAMP / P control ͒ d Ϸ P cAMP / P control for both P ␣-lactalbumin and P BSA ͓31͔. The model predictions shown in Fig. 6 for the peak increase by VEGF are from Ref. ͓7͔ ͑ϳ2.5-fold increase in the width of the cleft and ϳ50% degradation of surface glycocalyx͒ and those for cAMP effect are from Ref. ͓32͔ ͑the number of junction strands is in average increased from one to two in the cleft͒. To explain the structural changes in the abolishment of VEGF-induced hyperpermeability by pretreatment of 2 mM 8-bromo-cAMP, we used the results from our combined model predictions in Fig. 5͑a͒ for two junction strands when the reduced increase in the width of the cleft from ϳ2.5-fold to ϳ1.5-fold, and the recovery of the surface glycocalyx layer. Figure 6 shows that our model predictions are in good agreement with experimental data. If we use our previous data for P ␣-lactalbumin under the treatment of VEGF, 3.3-fold increase ͑n =17͒ instead of 2.7-fold ͑n =4͒ in the current study, the model predictions would fit better with the measured data. By the formation of new junction strands after pretreatment of 8-bromo-cAMP, the reinforced barriers in the cleft may diminish the increase in its width by VEGF and prevent the increase in microvessel permeability.
There are other structural changes due to VEGF, such as formation of transendothelial channels through fusion of caveolae ͓34,8,36͔, and due to cAMP, such as relaxation of cytoskeleton elements ͓43,19͔. Therefore, there may be other structural mechanisms responsible for the abolishment of VEGF-induced by cAMP under various conditions. In Figs. 5͑b͒-5͑d͒, we also examine the cAMP effect ͑increase the number of tight junction strands͒ on microvessel hyperpermeability due to degradation of the surface glycocalyx layer ͑Fig. 5͑b͒͒, increase the junctional pore size ͑Fig. 5͑c͒͒ and the number of pores ͑Fig. 5͑d͒͒. Figure 5 shows that increase the number of junction strands can abolish/ attenuate the permeability increase due to various structural changes, but to various levels for different sized solutes. In our previous study for VEGF-induced hyperpermeability ͓7͔, we found that the most likely structural changes are the increase in the width of the cleft to 2.5 folds of the control and partial degradation of the surface glycocalyx. Therefore, the predictions in Fig. 5͑a͒ for the change in cleft width are the corresponding change by cAMP on VEGF-induced hyperpermeability.
Due to the limitation of electron microscopy on the transient and dynamic changes by VEGF and cAMP, the model predictions from this study provide some suggestions about the destructionconstruction function of VEGF and cAMP for the interendothelial barriers based on the results from the transient ͑seconds to minutes͒ in vivo experiments. However, electron microscopy could be used for the final structural changes to confirm our model predictions.
In summary, the current study shows that pretreatment of 2 mM 8-bromo-cAMP completely abolishes the acute microvascular hyperpermeability induced by 1 nM VEGF in frog mesenteric microvessels. Combining these measured permeability data under various conditions and previous models for the interendothelial cleft ͓32,7,38͔, it is suggested that the possible structural changes for the abolishment of VEGF-induced hyperpermeability by cAMP are an increase in the number of the tight junction strands and the restoration of the surface glycocalyx.
